Summary
Hydrumedical S.A. (HYD) team is composed by a urologist and biomaterials scientists that will revolutionise the treatment of ureteral disorders. Hydrustent is a biodegradable, hydrogel-based, soft, lubricated, and flexible stent. These properties prevent bacterial adhesion (>80% of the stent-related complications) and encrustation development. Nowadays, the application of stents requires a 2nd removal procedure, a burden for patients and healthcare systems. Hydrustent is homogeneously degraded by the urine flow within 7-10 days, eliminating the need of further interventions for its removal. Hydrustent will bring huge health benefits for patients and reduce up to 60% of treatment costs (4.3B€ savings for the health system in EU+US). Validated by the urology community, with a global Ureteral Stents Market raising (~604M€ by 2030), if Hydrustent project is successfully implemented, we intend to reach the EU market in 2024 with profits amounting to 25M€, 5 years after product launch.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190169028 |
| Start date: | 01-12-2023 |
| End date: | 30-11-2025 |
| Total budget - Public funding: | 2 225 375,00 Euro - 1 522 762,00 Euro |
Cordis data
Original description
Hydrumedical S.A. (HYD) team is composed by a urologist and biomaterials scientists that will revolutionise the treatment of ureteral disorders. Hydrustent is a biodegradable, hydrogel-based, soft, lubricated, and flexible stent. These properties prevent bacterial adhesion (>80% of the stent-related complications) and encrustation development. Nowadays, the application of stents requires a 2nd removal procedure, a burden for patients and healthcare systems. Hydrustent is homogeneously degraded by the urine flow within 7-10 days, eliminating the need of further interventions for its removal. Hydrustent will bring huge health benefits for patients and reduce up to 60% of treatment costs (4.3B€ savings for the health system in EU+US). Validated by the urology community, with a global Ureteral Stents Market raising (~604M€ by 2030), if Hydrustent project is successfully implemented, we intend to reach the EU market in 2024 with profits amounting to 25M€, 5 years after product launch.Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)
